{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:20:57Z","timestamp":1770988857585,"version":"3.50.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion and 3.5-4 hours thereafter, thus making daratumumab-containing regimens burdensome for patients and health care resources. Preliminary data suggest that a rapid (90-minute) infusion of daratumumab is safe and does not increase IRRs. The rapid schedule was adopted by our centers since 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted an observational multi-center, real-life study to assess the safety of rapid daratumumab infusion protocol from the third administration in relapsed MM patients receiving daratumumab alone or in combination with lenalidomide-dexamethasone or bortezomib-dexamethasone. The primary endpoint was the safety of the rapid infusion protocol, particularly in terms of IRRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 134 MM patients were enrolled. IRRs occurred in 7 (5%) patients and were mostly mild (6\/7 of grade 1-2), with only 1 patient experiencing a grade 3 IRR. Due to the IRRs, 5 (3.7%) patients discontinued the rapid infusions and resumed daratumumab at the standard infusion rate, while 1 patient permanently discontinued daratumumab. In 4\/7 patients (57%), IRRs occurred while resuming rapid daratumumab infusions after a temporary interruption (2-4 months). No other adverse event was considered related to the rapid infusion protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings confirmed the safety of rapid daratumumab infusions starting from the third administration. In case of prolonged daratumumab interruption, it is advisable to resume infusions at the standard rate (3.5 hours) before switching to the rapid infusion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.851864","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T08:23:15Z","timestamp":1647246195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Francesca","family":"Bonello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Sandrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Vedovato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Bertiond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cattel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (CANDOR): Results From a Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 Antibodies in Multiple Myeloma: Back to the Future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00143","article-title":"Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab","volume":"14","author":"Nooka","year":"2018","journal-title":"J Oncol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0120-2","article-title":"Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma","volume":"32","author":"Barr","year":"2018","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLML.2020.02.014","article-title":"Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol","volume":"20","author":"Hamadeh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.570187","article-title":"Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients","volume":"10","author":"Gozzetti","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220951231","article-title":"Safety of Ninety-Minute Daratumumab Infusion","volume":"27","author":"Lombardi","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107815522110099","DOI":"10.1177\/10781552211009967","article-title":"Retrospective Review of Accelerated Daratumumab Administration","author":"Patel","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00226-3","article-title":"Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study","volume":"8","author":"Gordan","year":"2021","journal-title":"Drugs - Real World Outcomes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.018","article-title":"Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study","volume":"21","author":"Attardi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-Label, Non-Inferiority, Randomised, Phase 3 Trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients With Multiple Myeloma Across Lines of Therapy (PLEIADES): An Open-Label Phase II Study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.851864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T08:23:17Z","timestamp":1647246197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.851864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":18,"alternative-id":["10.3389\/fonc.2022.851864"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.851864","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"article-number":"851864"}}